Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Natera (NTRA) has released preliminary unaudited results for Q4 and full-year 2024, showing significant growth across key metrics. The company expects Q4 2024 revenues of approximately $472 million, up 52% from Q4 2023, and full-year 2024 revenues of approximately $1.7 billion, representing a 56% increase from 2023.
Test volumes showed strong growth, with 792,800 tests processed in Q4 2024 (26.5% increase) and 3,064,600 tests for full-year 2024 (22.8% increase). Notably, oncology testing saw substantial growth, with 150,800 oncology tests in Q4 2024, marking a 54.7% increase. The company achieved positive cash inflows of $45.8 million in Q4 2024 and $86.3 million for full-year 2024, compared to previous year’s cash outflows.
Natera (NTRA) ha pubblicato risultati preliminari non auditati per il quarto trimestre e l’anno intero 2024, mostrando una crescita significativa in diversi indicatori chiave. L’azienda prevede ricavi di circa $472 milioni per il Q4 2024, in aumento del 52% rispetto al Q4 2023, e ricavi per l’intero anno 2024 di circa $1,7 miliardi, che rappresentano un incremento del 56% rispetto al 2023.
I volumi dei test hanno mostrato una forte crescita, con 792.800 test elaborati nel Q4 2024 (incremento del 26,5%) e 3.064.600 test per l’intero anno 2024 (incremento del 22,8%). È importante notare che i test oncologici hanno visto una crescita sostanziale, con 150.800 test oncologici nel Q4 2024, segnando un aumento del 54,7%. L’azienda ha registrato flussi di cassa positivi di $45,8 milioni nel Q4 2024 e $86,3 milioni per l’intero anno 2024, rispetto ai flussi di cassa negativi dell’anno precedente.
Natera (NTRA) ha publicado resultados preliminares no auditados para el cuarto trimestre y el año completo de 2024, mostrando un crecimiento significativo en métricas clave. La compañía espera ingresos de aproximadamente $472 millones para el Q4 2024, un aumento del 52% en comparación con el Q4 2023, y ingresos de aproximadamente $1.7 mil millones para el año completo de 2024, lo que representa un incremento del 56% respecto a 2023.
Los volúmenes de pruebas mostraron un fuerte crecimiento, con 792,800 pruebas procesadas en el Q4 2024 (aumento del 26.5%) y 3,064,600 pruebas para el año completo de 2024 (aumento del 22.8%). Notablemente, las pruebas oncológicas experimentaron un crecimiento considerable, con 150,800 pruebas oncológicas en el Q4 2024, marcando un incremento del 54.7%. La compañía logró flujos de caja positivos de $45.8 millones en el Q4 2024 y $86.3 millones para el año completo de 2024, en comparación con los flujos de caja negativos del año anterior.
네이터라(NTRA)는 2024년 4분기와 연간 예비 감사 결과를 발표하며 주요 지표에서 상당한 성장을 보여주었습니다. 회사는 2024년 4분기 매출이 약 4억 7,200만 달러에 이를 것으로 예상하며, 이는 2023년 4분기 대비 52% 증가한 수치입니다. 2024년 연간 매출은 약 17억 달러로, 2023년 대비 56% 증가할 것으로 보입니다.
검사량은 강한 성장을 보이며, 2024년 4분기에 792,800건의 검사가 처리되었습니다 (26.5% 증가) 및 2024년 전체로 3,064,600건의 검사가 이루어졌습니다 (22.8% 증가). 특히, 종양학 검사에서 큰 성장이 있었으며, 2024년 4분기에 150,800건의 종양학 검사가 이루어졌습니다, 이는 54.7% 증가한 수치입니다. 회사는 2024년 4분기에는 4,580만 달러의 긍정적인 현금 유입을 기록했습니다 및 2024년 전체로 8,630만 달러의 현금 유입을 기록하여 이전 연도의 현금 유출과 비교되었습니다.
Natera (NTRA) a publié des résultats préliminaires non audités pour le quatrième trimestre et l’année complète 2024, montrant une croissance significative sur des indicateurs clés. La société prévoit des revenus d’environ 472 millions de dollars pour le Q4 2024, soit une augmentation de 52% par rapport au Q4 2023, et des revenus d’environ 1,7 milliard de dollars pour l’année entière 2024, représentant une augmentation de 56% par rapport à 2023.
Les volumes de tests ont montré une forte croissance, avec 792 800 tests traités au Q4 2024 (augmentation de 26,5%) et 3 064 600 tests pour l’année entière 2024 (augmentation de 22,8%). Notamment, les tests oncologiques ont connu une croissance substantielle, avec 150 800 tests oncologiques au Q4 2024, marquant une augmentation de 54,7%. L’entreprise a enregistré des flux de trésorerie positifs de 45,8 millions de dollars au Q4 2024 et 86,3 millions de dollars pour l’année entière 2024, par rapport aux sorties de trésorerie de l’année précédente.
Natera (NTRA) hat vorläufige, ungeprüfte Ergebnisse für das vierte Quartal und das Gesamtjahr 2024 veröffentlicht, die ein signifikantes Wachstum in wichtigen Kennzahlen zeigen. Das Unternehmen erwartet Umsätze von etwa 472 Millionen US-Dollar im Q4 2024, was einem Anstieg von 52% gegenüber Q4 2023 entspricht, und Umsätze von etwa 1,7 Milliarden US-Dollar für das Gesamtjahr 2024, was einem Zuwachs von 56% im Vergleich zum Jahr 2023 entspricht.
Die Testvolumina zeigten ein starkes Wachstum mit 792.800 durchgeführten Tests im Q4 2024 (26,5% Anstieg) und 3.064.600 Tests für das Gesamtjahr 2024 (22,8% Anstieg). Bemerkenswert ist das signifikante Wachstum im Bereich der Onkologie-Tests, mit 150.800 Onkologie-Tests im Q4 2024, was einem Anstieg von 54,7% entspricht. Das Unternehmen erzielte positive Cashflows von 45,8 Millionen US-Dollar im Q4 2024 und 86,3 Millionen US-Dollar für das Gesamtjahr 2024, im Vergleich zu den negativen Cashflows des Vorjahres.
Positive
- Revenue growth of 56% year-over-year, exceeding financial outlook by $53 million
- Record quarter for all three flagship products (Panorama, Prospera, Signatera)
- 54.7% increase in oncology test volume in Q4 2024
- Positive cash inflow of $86.3 million in 2024 vs outflow of $267.1 million in 2023
Insights
The preliminary Q4 and FY2024 results showcase exceptional performance across all key metrics. Revenue growth of 56% year-over-year to $1.7 billion significantly exceeded guidance, beating the top end by $53 million. The 52% Q4 revenue growth to $472 million demonstrates accelerating momentum.
Most notably, the company achieved positive cash inflows of $86.3 million for FY2024, a dramatic turnaround from $267.1 million cash outflow in 2023. This inflection to positive cash flow marks a important milestone in Natera’s path to sustainable profitability. The 54.9% growth in oncology tests, particularly the Signatera platform, indicates strong market penetration in the high-margin oncology segment.
The record volumes across all three flagship products – Panorama (prenatal), Prospera (transplant) and Signatera (oncology) – validate Natera’s multi-product strategy and suggest expanding market leadership. The sequential growth of 14,800 clinical oncology tests in Q4 points to strong commercial execution and growing physician adoption.
The explosive growth in test volumes reveals accelerating clinical adoption of Natera’s cell-free DNA technology platform. Processing nearly 3.1 million tests in 2024 represents significant market penetration, with particularly strong traction in oncology where clinical test volumes grew 63% to 498,300 tests.
The sequential increase of 14,800 clinical oncology tests in Q4 suggests growing physician confidence in using Signatera for cancer monitoring and recurrence detection. This adoption trend is important as clinical evidence continues to validate the utility of cell-free DNA testing in improving patient outcomes through earlier detection and more informed treatment decisions.
The record volumes across Panorama, Prospera and Signatera demonstrate that Natera’s technologies are increasingly becoming standard of care in their respective clinical applications. The company’s ability to scale test processing while maintaining quality and improving operational efficiency positions it well for continued market leadership in genetic testing.
2024 revenues are expected to increase by approximately 56% compared to 2023, which is approximately $53 million above top end of financial outlook
Additional business updates to be presented by Natera at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
AUSTIN, Texas–(BUSINESS WIRE)– Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today released preliminary unaudited results for the fourth quarter and full year ended December 31, 2024. The Company expects the following:
- Total revenues of approximately $472 million in the fourth quarter of 2024 compared to $311 million in the fourth quarter of 2023, an increase of approximately 52%.
- Total revenues of approximately $1.7 billion in the full year 2024 compared to $1.1 billion in the full year 2023, an increase of approximately 56%.
- Approximately 792,800 tests were processed in the fourth quarter of 2024 compared to 626,800 tests in the fourth quarter of 2023, an increase of 26.5%. This includes a record quarter for the Company’s three flagship products: Panorama™, Prospera™ and Signatera™.
- Approximately 3,064,600 tests were processed in the full year 2024 compared to 2,496,100 tests in the full year 2023, an increase of 22.8%.
- Approximately 150,800 oncology tests, including approximately 144,500 clinical oncology tests, were processed in the fourth quarter of 2024 compared to 97,500 oncology tests, including 90,500 clinical oncology tests, in the fourth quarter of 2023, an increase of 54.7%. Sequentially, clinical oncology tests increased by approximately 14,800 tests in the fourth quarter of 2024 over the third quarter of 2024.
- Approximately 528,200 oncology tests, including approximately 498,300 clinical oncology tests, were processed in the full year 2024 compared to 341,000 oncology tests, including 305,400 clinical oncology tests, in the full year 2023, an increase of 54.9%.
- The Company achieved positive cash inflows of approximately $45.8 million in the fourth quarter of 2024 compared to cash outflows of $60.8 million in the fourth quarter of 20231,2.
- The Company achieved positive cash inflows of approximately $86.3 million in the full year 2024 compared to cash outflows of $267.1 million in 20231,2.
These results will be included in a presentation at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 9:00 am PT, and also posted to the investor relations section of the Natera website at www.investor.natera.com. Natera will also present additional business updates at the J.P. Morgan conference.
Natera plans to release its complete fourth quarter and full year 2024 financial results during its earnings call in February 2025.
About Natera
Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 250 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit www.natera.com.
Forward-Looking Statements
This release contains forward-looking statements, including our preliminary operational and financial results for the fourth quarter and fiscal year ended December 31, 2024. The preliminary operational and financial results for the fourth quarter and fiscal year ended December 31, 2024 have not been audited by our independent registered public accounting firm and are based on management’s initial review of our operations and results for the completed fiscal year. These preliminary operational and financial results are subject to revision based upon our year-end closing procedures, final adjustments and the audit to be conducted by our independent registered public accounting firm. As a result, our actual operational and financial results may differ materially from these preliminary results. In addition, these preliminary operational and financial results are not a comprehensive statement of our operational and financial results for the fourth quarter and for fiscal 2024, and should not be viewed as a substitute for full, audited financial statements prepared in accordance with generally accepted accounting principles. Any forward-looking statements contained in this release are based upon Natera’s current plans, estimates, and expectations as of the date of this release, and are not a representation that such plans, estimates, or expectations will be achieved. Subsequent events may cause these expectations to change, and Natera disclaims any obligation to update the forward-looking statements in the future.
Our forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including: our preliminary operational and financial results for the fourth quarter and for fiscal 2024 are subject to material changes and adjustments as noted above; we face numerous uncertainties and challenges in achieving our financial projections and goals; we have incurred net losses since our inception and we anticipate that we will continue to incur net losses for the foreseeable future; our quarterly results may fluctuate from period to period; our estimates of market opportunity and forecasts of market growth may prove to be inaccurate. Additional risks and uncertainties that could affect our financial results are discussed in greater detail in the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our most recent filings on Forms 10-K and 10-Q and in other filings that we make with the SEC from time to time. These documents are available at www.investor.natera.com and on the SEC’s website at www.sec.gov.
1 Non-GAAP cash inflow for the quarter and year ended December 31, 2024 are estimated based on estimated unaudited GAAP Statement of Cash Flows amounts including net cash from operating activities, net cash from financing activities, and net cash from investing activities excluding amounts related to short term investments.
2 Non-GAAP cash outflow of $60.8 million for the quarter ended December 31, 2023 are derived from GAAP Statement of Cash Flows amounts including $58.1 million net cash from operating activities, $9.5 million net cash from investing activities excluding amounts related to short term investments offset by $6.8 million net cash from financing activities.
Non-GAAP cash outflow of $267.1 million for the year ended December 31, 2023 are derived from GAAP Statement of Cash Flows amounts including $246.9 million net cash from operating activities, $39.2 million net cash from investing activities excluding amounts related to short term investments, offset by $19.0 million net cash from financing activities excluding $235.4 million cash inflows from the September 2023 public offering.
Management uses non-GAAP cash flow as an indicator of the Company’s operational cash generating capabilities.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250112651894/en/
Investor Relations: Mike Brophy, CFO, Natera, Inc., 650-249-9090, investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com
Source: Natera, Inc.
FAQ
What was Natera’s (NTRA) revenue growth in Q4 2024?
Natera’s Q4 2024 revenues were approximately $472 million, representing a 52% increase compared to Q4 2023’s $311 million.
How many tests did Natera (NTRA) process in full-year 2024?
Natera processed approximately 3,064,600 tests in full-year 2024, a 22.8% increase from 2,496,100 tests in 2023.
What was Natera’s (NTRA) cash flow performance in 2024?
Natera achieved positive cash inflows of $86.3 million in 2024, compared to cash outflows of $267.1 million in 2023.
How did Natera’s (NTRA) oncology testing perform in Q4 2024?
Natera processed 150,800 oncology tests in Q4 2024, including 144,500 clinical oncology tests, representing a 54.7% increase from Q4 2023.
By how much did Natera (NTRA) exceed its financial outlook in 2024?
Natera exceeded the top end of its financial outlook by approximately $53 million in 2024.
